Man Gets Into a Tesla… What Happens Next Will Shock Everyone (Video)
"Hi, I'm Jeff Brown… I'm about to get in this Tesla and drive up to a location just a few miles from here to show you Elon Musk's next big project…

What happens next will shock you…"
Click here to see what happened.
pixel

BMRN Insider Trading (BioMarin Pharmaceutical)

Insider Ownership Percentage: 2.15%
Insider Buying (Last 12 Months): $1,001,728.00
Insider Selling (Last 12 Months): $37,178,623.80

BioMarin Pharmaceutical Insider Trading History Chart

BioMarin Pharmaceutical Share Price & Price History

$83.32
▲ +1.17 (1.42%)
As of 02/24/2021 01:00 AM ET
Days: 30 | 90 | 365
Warren Buffett has been on a selling spree
Through Berkshire Hathaway…Warren Buffett recently dumped $800 million of Apple stock…

And bought this instead!

He’s now moved $3.8 BILLION in a tiny niche of the tech sector billionaires are flocking to…
Click to see what Buffett knows

BioMarin Pharmaceutical Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/19/2021Jean Jacques BienaimeCEOSell7,000$83.58$585,060.00302,552  
2/17/2021Jean Jacques BienaimeCEOSell8,000$84.54$676,320.00303,552  
1/29/2021Jean Jacques BienaimeCEOSell8,334$82.67$688,971.78303,885  
1/27/2021Jean Jacques BienaimeCEOSell8,333$85.49$712,388.17303,885  
12/28/2020Jean Jacques BienaimeCEOSell1,500$88.77$133,155.00297,052  
10/14/2020Jeffrey Robert AjerEVPSell2,121$79.91$169,489.1161,281  
8/31/2020David E I PyottDirectorBuy12,800$78.26$1,001,728.0029,840  
8/3/2020Michael G GreyDirectorSell2,500$120.35$300,875.0045,340  
7/20/2020Henry J FuchsInsiderSell126,389$130.00$16,430,570.00104,245  
7/13/2020Henry J FuchsInsiderSell23,011$130.00$2,991,430.00102,995  
6/26/2020Willard H DereDirectorSell4,430$123.61$547,592.3013,290  
6/19/2020Jeffrey Robert AjerEVPSell15,000$124.00$1,860,000.0063,402  
6/5/2020V Bryan LawlisDirectorSell4,430$107.46$476,047.8018,850  
5/8/2020Jean Jacques BienaimeCEOSell20,000$91.72$1,834,400.00318,552  
5/4/2020Jean Jacques BienaimeCEOSell5,000$88.00$440,000.00298,552  
5/1/2020George Eric DavisEVPSell12,504$89.38$1,117,607.5278,181  
5/1/2020Jean Jacques BienaimeCEOSell4,000$89.38$357,520.00298,552  
4/28/2020Jean Jacques BienaimeCEOSell20,000$97.58$1,951,600.00318,213  
4/24/2020Henry J FuchsInsiderSell20,000$95.88$1,917,600.00109,014  
4/20/2020Henry J FuchsInsiderSell17,213$90.00$1,549,170.00122,656  
4/9/2020Jean Jacques BienaimeCEOSell10,000$79.06$790,600.00308,213  
4/8/2020Jeffrey Robert AjerEVPSell2,407$79.98$192,511.8663,064  
4/1/2020Jeffrey Robert AjerEVPSell1,537$82.00$126,034.0065,471  
3/24/2020Jeffrey Robert AjerEVPSell2,041$74.36$151,768.7668,626  
3/17/2020V Bryan LawlisDirectorSell3,750$75.39$282,712.5018,980  
3/9/2020Jean Jacques BienaimeCEOSell10,000$89.52$895,200.00296,443  
1/14/2020Jean Jacques BienaimeCEOSell8,000$87.95$703,600.00335,530  
1/7/2020Jean Jacques BienaimeCEOSell3,000$84.46$253,380.00330,530  
12/27/2019Jean Jacques BienaimeCEOSell5,000$86.16$430,800.00  
12/17/2019V Bryan LawlisDirectorSell3,750$83.36$312,600.0027,340  
11/26/2019George Eric DavisEVPSell3,190$79.66$254,115.4068,709  
11/22/2019Jean Jacques BienaimeCEOSell10,000$77.60$776,000.00327,070  
10/25/2019Jean Jacques BienaimeCEOSell5,000$69.55$347,750.00332,520  
9/17/2019V Bryan LawlisDirectorSell3,750$74.47$279,262.5027,340  
6/17/2019V Bryan LawlisDirectorSell3,750$81.08$304,050.0027,340  
5/10/2019Jean Jacques BienaimeCEOSell10,000$82.52$825,200.00336,520  
5/8/2019Jean Jacques BienaimeCEOSell4,000$82.16$328,640.00326,520  
4/26/2019Jean Jacques BienaimeCEOSell3,000$82.88$248,640.00329,211  
4/12/2019Jean Jacques BienaimeCEOSell4,000$89.12$356,480.00325,211  
4/8/2019Jean Jacques BienaimeCEOSell3,000$91.87$275,610.00327,211  
4/5/2019Brian MuellerSVPSell2,953$94.00$277,582.0013,660  
4/5/2019Jean Jacques BienaimeCEOSell3,000$93.37$280,110.00327,211  
4/1/2019Daniel K SpiegelmanCFOSell13,473$89.00$1,199,097.0047,510  
3/27/2019Daniel K SpiegelmanCFOSell100$90.00$9,000.0060,983  
3/27/2019V Bryan LawlisDirectorSell2,150$89.76$192,984.0021,310  
3/25/2019George Eric DavisEVPSell3,363$87.86$295,473.1875,253  
3/25/2019Henry J FuchsInsiderSell5,932$87.86$521,185.52130,468  
3/25/2019Jean Jacques BienaimeCEOSell4,000$87.86$351,440.00323,211  
3/21/2019Jeffrey Robert AjerEVPSell4,519$89.98$406,619.6256,659  
3/19/2019Jeffrey Robert AjerEVPSell3,728$93.07$346,964.9659,248  
3/18/2019Henry J FuchsInsiderSell9,597$94.09$902,981.73133,061  
3/15/2019Jean Jacques BienaimeCEOSell4,000$94.40$377,600.00300,558  
3/12/2019Jean Jacques BienaimeCEOSell9,000$90.06$810,540.00333,701  
3/7/2019Jean Jacques BienaimeCEOSell4,000$90.78$363,120.00332,701  
3/4/2019Henry J FuchsInsiderSell2,196$95.00$208,620.00142,504  
2/27/2019Jean Jacques BienaimeCEOSell4,000$91.78$367,120.00292,290  
2/21/2019Jean Jacques BienaimeCEOSell3,000$90.12$270,360.00291,290  
2/14/2019Jean Jacques BienaimeCEOSell4,000$95.20$380,800.00292,290  
2/5/2019Jean Jacques BienaimeCEOSell4,000$98.63$394,520.00292,290  
1/22/2019Jean Jacques BienaimeCEOSell3,000$96.82$290,460.00291,290  
1/14/2019Jean Jacques BienaimeCEOSell4,000$93.79$375,160.00292,290  
1/10/2019Jean Jacques BienaimeCEOSell3,000$90.55$271,650.00291,290  
1/7/2019Jean Jacques BienaimeCEOSell3,000$87.58$262,740.00291,290  
12/28/2018Jean Jacques BienaimeCEOSell3,000$84.04$252,120.00  
12/28/2018Jean Jacques BienaimeCEOSell3,000$84.04$252,120.00291,290  
12/27/2018V Bryan LawlisDirectorSell2,150$82.53$177,439.5021,310  
12/26/2018Jean Jacques BienaimeCEOSell4,000$80.50$322,000.00292,290  
12/14/2018Jean Jacques BienaimeCEOSell2,000$92.64$185,280.00290,290  
12/12/2018Jean Jacques BienaimeCEOSell2,000$93.12$186,240.00290,290  
11/14/2018Jeffrey Robert AjerEVPSell9,000$92.15$829,350.0058,135  
11/1/2018Jean Jacques BienaimeCEOSell4,000$92.55$370,200.00292,290  
10/3/2018Jean Jacques BienaimeCEOSell1,500$99.36$149,040.00287,790  
10/3/2018Jeffrey Robert AjerEVPSell1,000$98.98$98,980.0049,135  
9/27/2018V Bryan LawlisDirectorSell2,150$97.93$210,549.5021,310  
9/13/2018George Eric DavisEVPSell12,000$99.57$1,194,840.0074,950  
9/13/2018Richard A MeierDirectorSell3,000$99.24$297,720.0081,610  
9/5/2018Elaine J HeronDirectorSell1,000$96.94$96,940.0041,685  
9/4/2018Jean Jacques BienaimeCEOSell1,500$98.16$147,240.00286,790  
8/27/2018Henry J FuchsInsiderSell25,000$99.50$2,487,500.00142,667  
8/27/2018Richard A MeierDirectorSell2,000$100.12$200,240.0069,610  
8/24/2018Henry J FuchsInsiderSell12,500$99.00$1,237,500.00142,667  
8/21/2018Alan LewisDirectorSell4,200$100.09$420,378.0021,160  
8/7/2018Brian MuellerSVPSell2,500$104.50$261,250.0014,093  
8/7/2018Robert BaffiEVPSell5,173$105.00$543,165.0083,276  
7/23/2018Jean Jacques BienaimeCEOSell1,500$101.69$152,535.00286,790  
6/27/2018V Bryan LawlisDirectorSell2,150$93.52$201,068.0021,310  
6/22/2018Brian MuellerSVPSell3,145$99.50$312,927.5012,375  
6/22/2018Daniel K SpiegelmanCFOSell10,000$99.00$990,000.0051,542  
6/22/2018Robert BaffiEVPSell6,949$99.00$687,951.0090,225  
6/15/2018Brian MuellerSVPSell2,021$94.50$190,984.5013,029  
6/14/2018Henry J FuchsInsiderSell31,000$90.00$2,790,000.00157,167  
6/11/2018Jeffrey Robert AjerEVPSell1,436$90.31$129,685.1650,135  
5/17/2018Jean Jacques BienaimeCEOSell18,750$88.66$1,662,375.00309,350  
5/15/2018Jean Jacques BienaimeCEOSell37,500$88.75$3,328,125.00309,350  
5/11/2018Jean Jacques BienaimeCEOSell18,750$88.42$1,657,875.00  
5/10/2018Brian MuellerSVPSell2,450$89.50$219,275.0017,846  
5/7/2018Jeffrey Robert AjerEVPSell309$85.96$26,561.6453,223  
4/24/2018Jean Jacques BienaimeCEOSell20,000$82.43$1,648,600.00300,031  
4/23/2018Daniel K SpiegelmanCFOSell11,059$82.15$908,496.8562,543  
4/20/2018Jean Jacques BienaimeCEOSell10,000$83.65$836,500.00300,031  
4/17/2018V Bryan LawlisDirectorSell3,750$85.00$318,750.0018,610  
4/2/2018Henry J FuchsInsiderSell10,000$80.12$801,200.00160,026  
4/2/2018Jeffrey Robert AjerEVPSell2,119$80.12$169,774.2852,914  
3/29/2018Jeffrey Robert AjerEVPSell1,537$79.69$122,483.5355,033  
3/23/2018George Eric DavisEVPSell3,350$81.35$272,522.5087,989  
3/21/2018Jeffrey Robert AjerEVPSell4,368$83.90$366,475.2060,153  
3/16/2018George Eric DavisEVPSell3,818$83.88$320,253.8494,634  
3/15/2018Jean Jacques BienaimeCEOSell15,000$84.73$1,270,950.00279,674  
3/9/2018Jeffrey Robert AjerEVPSell2,972$82.39$244,863.0855,332  
3/5/2018George Eric DavisEVPSell2,105$79.04$166,379.2090,089  
See Full Table

SEC Filings (Institutional Ownership Changes) for BioMarin Pharmaceutical (NASDAQ:BMRN)

97.65% of BioMarin Pharmaceutical stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

BioMarin Pharmaceutical Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in Company
2/24/2021Alyeska Investment Group L.P.51,888$4.55M0.1%-77.2%0.029%
2/24/2021Bank Julius Baer & Co. Ltd Zurich14,049$1.23M0.0%+92.4%0.008%
2/23/2021Principal Financial Group Inc.58,777$5.15M0.0%+27.4%0.032%
2/19/2021AtonRa Partners5,922$0.52M0.3%N/A0.003%
2/19/2021Berman Capital Advisors LLC581$50K0.0%+600.0%0.000%
2/19/2021National Pension Service301,968$26.48M0.1%+19.0%0.166%
2/18/2021Truist Financial Corp117,689$10.32M0.0%+18.7%0.065%
2/17/2021Twinbeech Capital LP6,974$0.61M0.1%N/A0.004%
2/17/2021United Capital Financial Advisers LLC9,267$0.81M0.0%-49.0%0.005%
2/17/2021Freedman Financial Associates Inc.381$33K0.0%N/A0.000%
2/17/2021Canada Pension Plan Investment Board60,980$5.35M0.0%-15.0%0.034%
2/17/2021Cetera Investment Advisers2,695$0.24M0.0%N/A0.001%
2/16/2021Tokio Marine Asset Management Co. Ltd.26,340$2.31M0.3%-2.9%0.015%
2/16/2021HN Saltoro Capital LP8,000$0.70M0.3%N/A0.004%
2/16/2021Squarepoint Ops LLC57,750$5.06M0.0%+123.3%0.032%
2/16/2021Alyeska Investment Group L.P.51,888$4.55M0.1%-77.2%0.029%
2/16/2021Brookfield Asset Management Inc.52,907$4.64M0.0%N/A0.029%
2/16/2021Mariner LLC25,307$2.22M0.0%+64.5%0.014%
2/16/2021Toroso Investments LLC2,461$0.22M0.0%N/A0.001%
2/16/2021Paloma Partners Management Co7,278$0.64M0.0%-79.5%0.004%
2/16/2021LMR Partners LLP28,500$2.50M0.0%N/A0.016%
2/16/2021Neo Ivy Capital Management687$60K0.1%N/A0.000%
2/16/2021Rice Hall James & Associates LLC75,748$6.64M0.2%-6.3%0.042%
2/16/2021Tudor Investment Corp Et Al17,187$1.51M0.0%+350.0%0.009%
2/16/2021Captrust Financial Advisors3,309$0.29M0.0%-11.3%0.002%
2/16/2021Guggenheim Capital LLC61,777$5.42M0.0%-43.0%0.034%
2/16/2021Price T Rowe Associates Inc. MD2,064,582$181.04M0.0%+5.6%1.137%
2/16/2021Sivik Global Healthcare LLC80,000$7.02M2.9%+23.1%0.044%
2/16/2021Avoro Capital Advisors LLC1,650,000$144.69M2.5%-5.7%0.909%
2/16/2021Engineers Gate Manager LP8,023$0.70M0.0%N/A0.004%
2/16/2021Avidity Partners Management LP992,900$87.07M2.8%N/A0.547%
2/16/2021Gyon Technologies Capital Management LP3,627$0.32M0.1%-41.7%0.002%
2/16/2021Janus Henderson Group PLC5,686,942$498.68M0.2%+9.1%3.133%
2/16/2021Prelude Capital Management LLC7,105$0.62M0.0%+2,268.3%0.004%
2/16/2021ExodusPoint Capital Management LP26,454$2.32M0.0%-33.8%0.015%
2/16/2021Benjamin F. Edwards & Company Inc.3,063$0.27M0.0%+101.4%0.002%
2/16/2021Charles Schwab Investment Management Inc.694,230$60.88M0.0%+1.7%0.382%
2/13/2021Essex Investment Management Co. LLC30,720$2.69M0.3%+95.9%0.017%
2/13/2021American International Group Inc.4,332$0.38M0.0%-71.8%0.002%
2/12/2021Stifel Financial Corp177,105$15.53M0.0%+4.5%0.098%
2/12/2021Laurion Capital Management LP11,973$1.05M0.0%N/A0.007%
2/12/2021Federated Hermes Inc.5,047$0.44M0.0%+35.6%0.003%
2/12/2021Corient Capital Partners LLC2,292$0.20M0.0%N/A0.001%
2/12/2021Raymond James Financial Services Advisors Inc.5,368$0.47M0.0%+26.4%0.003%
2/12/2021LPL Financial LLC66,018$5.79M0.0%+37.5%0.036%
2/12/2021Amalgamated Bank9,287$0.81M0.0%-1.4%0.005%
2/12/2021Public Employees Retirement System of Ohio91,460$8.02M0.0%+23.4%0.050%
2/12/2021Ossiam743$65K0.0%+524.4%0.000%
2/12/2021Nomura Asset Management Co. Ltd.170,370$14.94M0.1%-55.0%0.094%
2/12/2021Eaton Vance Management18,018$1.58M0.0%+3.2%0.010%
2/12/2021Edgewood Management LLC15,000$1.32M0.0%+50.0%0.008%
2/12/2021Magnetar Financial LLC4,511$0.40M0.0%N/A0.002%
2/12/2021Nordea Investment Management AB8,628$0.76M0.0%+12.3%0.005%
2/12/2021Vontobel Holding Ltd.7,920$0.68M0.0%N/A0.004%
2/12/2021Healthcare of Ontario Pension Plan Trust Fund978$86K0.0%N/A0.001%
2/12/2021Virtus ETF Advisers LLC7,346$0.64M0.3%+32.9%0.004%
2/12/2021Motley Fool Wealth Management LLC246,881$21.65M1.0%+0.7%0.136%
2/12/2021M&T Bank Corp9,380$0.82M0.0%+2.1%0.005%
2/12/2021Mercer Global Advisors Inc. ADV26,565$2.33M0.0%+1.2%0.015%
2/11/2021Eqis Capital Management Inc.12,343$1.08M0.1%-12.0%0.007%
2/11/2021Dodge & Cox9,796,924$859.09M0.7%+26.9%5.397%
2/11/2021Synovus Financial Corp49,245$4.32M0.0%+0.9%0.027%
2/11/2021Northern Trust Corp1,184,564$103.88M0.0%-3.0%0.653%
2/11/2021Baird Financial Group Inc.290,001$25.43M0.1%+1.4%0.160%
2/11/2021Public Employees Retirement Association of Colorado26,189$2.30M0.0%-88.3%0.014%
2/11/2021Argent Trust Co6,454$0.57M0.0%+12.0%0.004%
2/11/2021Berman Capital Advisors LLC581$50K0.0%+600.0%0.000%
2/11/2021First Mercantile Trust Co.2,660$0.23M0.0%-12.5%0.001%
2/11/2021Heritage Trust Co6,098$0.54M0.1%+19.5%0.003%
2/11/2021Valeo Financial Advisors LLC4,273$0.38M0.0%+557.4%0.002%
2/11/2021Teacher Retirement System of Texas16,526$1.45M0.0%-24.5%0.009%
2/11/2021Slow Capital Inc.19,331$1.70M0.4%+4.8%0.011%
2/11/2021Steward Partners Investment Advisory LLC425$37K0.0%+189.1%0.000%
2/11/2021Asymmetry Capital Management L.P.88,195$7.73M3.5%N/A0.049%
2/11/2021Skandinaviska Enskilda Banken AB publ 102,201$8.96M0.1%+4.3%0.056%
2/11/2021First Horizon Advisors Inc.656$57K0.0%+45.1%0.000%
2/11/2021Veriti Management LLC1,849$0.16M0.0%N/A0.001%
2/11/2021Nicholas Investment Partners LP81,530$7.15M0.6%-97.6%0.045%
2/10/2021Rhumbline Advisers204,097$17.90M0.0%-5.4%0.112%
2/10/2021Aequim Alternative Investments LP46,400$0.12M0.1%+314.3%0.026%
2/10/2021Mackenzie Financial Corp7,941$0.70M0.0%+14.5%0.004%
2/10/2021Clearbridge Investments LLC6,022,412$528.11M0.4%-2.4%3.318%
2/10/2021QS Investors LLC4,174$0.37M0.0%+13.0%0.002%
2/10/2021Parnassus Investments CA1,518,951$133.20M0.4%+712.0%0.837%
2/10/2021Mid Atlantic Financial Management Inc. ADV2,718$0.24M0.0%-5.3%0.001%
2/10/2021Ironsides Asset Advisors LLC7,346$0.64M0.2%+2.2%0.004%
2/10/2021Jupiter Asset Management Ltd.5,416$0.47M0.0%N/A0.003%
2/10/2021Aviva PLC61,485$5.39M0.0%+5.5%0.034%
2/10/2021Panagora Asset Management Inc.11,364$1M0.0%+34.7%0.006%
2/10/2021FineMark National Bank & Trust2,500$0.22M0.0%N/A0.001%
2/10/2021Korea Investment CORP51,000$4.47M0.0%-7.3%0.028%
2/10/2021HighTower Advisors LLC4,013$0.35M0.0%N/A0.002%
2/10/2021CKW Financial Group450$39K0.0%+80.0%0.000%
2/10/2021Ilmarinen Mutual Pension Insurance Co70,000$6.14M0.1%+100.0%0.039%
2/9/2021Hancock Whitney Corp3,440$0.30M0.0%-5.7%0.002%
2/9/2021Advisory Services Network LLC534$47K0.0%-94.8%0.000%
2/9/2021Fiera Capital Corp706,972$61.99M0.2%-0.3%0.389%
2/9/2021Varma Mutual Pension Insurance Co25,000$2.19M0.0%-50.0%0.014%
2/9/2021Van ECK Associates Corp193,013$16.93M0.0%+13.7%0.106%
2/9/2021Keybank National Association OH65,490$5.74M0.0%+448.1%0.036%
Data available starting January 2016

See Full Table
BioMarin Pharmaceutical logo
BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. Its clinical and pre-clinical product pipeline includes valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide, a peptide therapeutic that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; and BMN 307, an AAV5 mediated gene therapy to normalize blood phenylalanine concentration levels in patients with phenylketonuria. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has collaboration and license agreements with Sarepta Therapeutics and Asubio Pharma Co., Ltd.; and a preclinical collaboration and license agreement with DiNAQOR AG for the development of gene therapies to treat rare genetic cardiomyopathies. The company was founded in 1996 and is headquartered in San Rafael, California.
Read More

Today's Range

Now: $83.32
$82.20
$84.52

50 Day Range

MA: $84.91
$81.06
$90.69

52 Week Range

Now: $83.32
$68.25
$131.95

Volume

1,027,818 shs

Average Volume

1,343,253 shs

Market Capitalization

$15.13 billion

P/E Ratio

19.07

Dividend Yield

N/A

Beta

0.71

Who are the company insiders with the largest holdings of BioMarin Pharmaceutical?

BioMarin Pharmaceutical's top insider shareholders include:
  1. Jean Jacques Bienaime (CEO)
  2. Henry J Fuchs (Insider)
  3. George Eric Davis (EVP)
  4. Jeffrey Robert Ajer (EVP)
  5. Daniel K Spiegelman (CFO)
  6. Michael G Grey (Director)
  7. David E I Pyott (Director)
  8. V Bryan Lawlis (Director)
  9. Brian Mueller (SVP)
  10. Willard H Dere (Director)

Who are the major institutional investors of BioMarin Pharmaceutical?

BioMarin Pharmaceutical's top institutional investors include:
  1. Primecap Management Co. CA — 10.00%
  2. Dodge & Cox — 5.40%
  3. Clearbridge Investments LLC — 3.32%
  4. Janus Henderson Group PLC — 3.13%
  5. Price T Rowe Associates Inc. MD — 1.14%
  6. Avoro Capital Advisors LLC — 0.91%

Which major investors are selling BioMarin Pharmaceutical stock?

During the previous quarter, BMRN stock was sold by these institutional investors:
  1. Nicholas Investment Partners LP
  2. Russell Investments Group Ltd.
  3. Daiwa Securities Group Inc.
  4. Sumitomo Mitsui Trust Holdings Inc.
  5. Frontier Capital Management Co. LLC
  6. Rhenman & Partners Asset Management AB
  7. Nomura Asset Management Co. Ltd.
  8. Public Employees Retirement Association of Colorado
During the previous year, company insiders that have sold BioMarin Pharmaceutical company stock include:
  1. Jean Jacques Bienaime (CEO)
  2. Henry J Fuchs (Insider)
  3. George Eric Davis (EVP)
  4. Jeffrey Robert Ajer (EVP)
  5. Daniel K Spiegelman (CFO)
  6. Michael G Grey (Director)
  7. David E I Pyott (Director)

Which major investors are buying BioMarin Pharmaceutical stock?

During the last quarter, BMRN stock was bought by institutional investors including:
  1. Dodge & Cox
  2. Parnassus Investments CA
  3. Avidity Partners Management LP
  4. Janus Henderson Group PLC
  5. Alliancebernstein L.P.
  6. Price T Rowe Associates Inc. MD
  7. Asymmetry Capital Management L.P.
  8. State of Wisconsin Investment Board
The Top Stock to Watch as the Future Turns Green
California is the biggest market in the world for MJ and one company is about to open one of the largest facilities in the state. This could be the hottest MJ ground-floor play around!
Continue Reading
pixel